Real world treatment practices and outcomes of metastatic Merkel cell carcinoma: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Early-stage cancer immunotherapy represents a promising yet underexplored frontier in cancer research. While immunotherapeutic strategies have achieved ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...
Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...
The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...
The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...
Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially within oncology by using multi-omics ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results